12 Biotechnology companies are scored. Their average composite is 63.5, and 0 are in the A range (76+). The leader is Royalty Pharma plc (RPRX) at 75.1 (B+). This industry belongs to the Healthcare sector.
| # | Company | Composite | Grade | Industry opportunity | Stock selection | KPI momentum | Catalyst watch | Price | Expansion | Quality | Trend | Valuation gap |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Royalty Pharma plc (RPRX) | 75.1 | B+ | 77 | 90 | 99 | 74 | 59 | 52 | 80 | 82 | -17.8% |
| 2 | BeOne Medicines Ltd ADR (ONC) | 73.0 | B+ | 77 | 85 | 99 | 73 | 26 | 93 | 75 | 55 | -26.6% |
| 3 | Regeneron Pharmaceuticals Inc. (REGN) | 72.8 | B+ | 77 | 82 | 83 | 76 | 57 | 51 | 68 | 61 | +7.7% |
| 4 | Vertex Pharmaceuticals Incorporated (VRTX) | 68.1 | B | 77 | 80 | 75 | 80 | 29 | 64 | 84 | 56 | -7.5% |
| 5 | argenx SE ADR (ARGX) | 68.0 | B | 77 | 80 | 78 | 75 | 28 | 92 | 80 | 35 | -27.3% |
| 6 | Incyte Corporation (INCY) | 68.0 | B | 77 | 80 | 75 | 79 | 62 | 66 | 89 | 52 | -18.8% |
| 7 | Alnylam Pharmaceuticals Inc. (ALNY) | 61.4 | B- | 77 | 79 | 77 | 67 | 40 | 97 | 74 | 3 | -18.1% |
| 8 | Bio-Techne Corporation (TECH) | 60.4 | B- | 77 | 61 | 43 | 69 | 18 | 52 | 61 | 58 | -22.2% |
| 9 | Insmed Inc. (INSM) | 60.0 | B- | 77 | 87 | 93 | 81 | 11 | 99 | 19 | 4 | -48.5% |
| 10 | Moderna, Inc. (MRNA) | 58.1 | B- | 77 | 84 | 87 | 81 | 3 | 44 | 3 | 85 | +170.9% |
| 11 | Revolution Medicines Inc. (RVMD) | 55.5 | C+ | 77 | 73 | 62 | 67 | 2 | 55 | 1 | 68 | -28.5% |
| 12 | BioNTech SE ADR (BNTX) | 41.2 | C- | 77 | 57 | 30 | 63 | 17 | 7 | 25 | 17 | -22.3% |
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.